For Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, the mission is clear: bring better cancer ...

Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...

In the world of oncology drug development, the standard playbook is simple: race to earlier lines of treatment, where patient ...

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

With the best-selling medication in the world, tirzepatide, and a record-setting $1 trillion valuation to go with it, Eli ...

Eli Lilly 's (NYSE: LLY) share price has soared over the past five years (up 530%). In fact, it's hard to find a single ...

The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint. American ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.